Online inquiry

IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8662MR)

This product GTTS-WQ8662MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD38 gene. The antibody can be applied in Multiple myeloma (MM), AL amyloidosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001775.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 952
UniProt ID P28907
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8662MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6037MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ853MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ15457MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ6142MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ830MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ1379MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ5891MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ9882MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA KB001-A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW